Aduro BioTech (ADRO) Research Coverage Started at Leerink Swann

Share on StockTwits

Equities research analysts at Leerink Swann assumed coverage on shares of Aduro BioTech (NASDAQ:ADRO) in a research report issued to clients and investors on Monday, The Fly reports. The firm set an “outperform” rating on the biotechnology company’s stock.

A number of other research analysts have also recently commented on ADRO. Zacks Investment Research raised Aduro BioTech from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Wednesday, December 19th. BidaskClub cut Aduro BioTech from a “hold” rating to a “sell” rating in a research report on Friday, March 29th. Oppenheimer reaffirmed a “buy” rating on shares of Aduro BioTech in a research report on Tuesday, March 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.30 price target on shares of Aduro BioTech in a research report on Wednesday, December 19th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $7.41.

Shares of NASDAQ ADRO opened at $3.67 on Monday. Aduro BioTech has a one year low of $2.34 and a one year high of $9.00. The firm has a market cap of $301.04 million, a PE ratio of -3.16 and a beta of 2.06.

Aduro BioTech (NASDAQ:ADRO) last issued its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.10). Aduro BioTech had a negative net margin of 632.05% and a negative return on equity of 54.84%. As a group, sell-side analysts forecast that Aduro BioTech will post -0.78 earnings per share for the current fiscal year.

In other news, insider Elsas Andrea Van sold 6,844 shares of the company’s stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $4.25, for a total transaction of $29,087.00. Following the transaction, the insider now owns 245,638 shares of the company’s stock, valued at approximately $1,043,961.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jennifer Lew sold 18,601 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $4.07, for a total value of $75,706.07. Following the transaction, the chief financial officer now directly owns 139,380 shares in the company, valued at approximately $567,276.60. The disclosure for this sale can be found here. Insiders have sold a total of 31,526 shares of company stock worth $128,874 in the last ninety days. Insiders own 5.20% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its holdings in Aduro BioTech by 11.3% during the 4th quarter. Geode Capital Management LLC now owns 627,397 shares of the biotechnology company’s stock valued at $1,656,000 after acquiring an additional 63,447 shares during the period. Norges Bank purchased a new stake in Aduro BioTech during the 4th quarter valued at about $370,000. Dimensional Fund Advisors LP boosted its holdings in Aduro BioTech by 90.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 560,660 shares of the biotechnology company’s stock valued at $1,480,000 after acquiring an additional 266,372 shares during the period. Millennium Management LLC boosted its holdings in Aduro BioTech by 25.0% during the 4th quarter. Millennium Management LLC now owns 116,376 shares of the biotechnology company’s stock valued at $307,000 after acquiring an additional 23,310 shares during the period. Finally, Legal & General Group Plc boosted its holdings in Aduro BioTech by 25.6% during the 4th quarter. Legal & General Group Plc now owns 30,303 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 6,184 shares during the period. Institutional investors own 44.82% of the company’s stock.

Aduro BioTech Company Profile

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Recommended Story: How to calculate the annual rate of depreciation

The Fly

Analyst Recommendations for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.